BioSpace News Archive

POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radiopharmaceutical drug development and commercialization

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2019 financial results on Tuesday, March 3, after the close of the U.S. financial markets

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the fourth quarter and year-ended December 31, 2019, after the close of market on Tuesday, March 10, 2020.

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled “Building MOMENTUM for Patients with Myelofibrosis” at the Cowen 40th Annual Health Care Conference

Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that management will host a conference call and live audio webcast on March 2, 2020 at 8:30 a.m. ET to discuss fourth quarter and full year 2019 results and provide a general business update.

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40th Annual Health Care Conference

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,568,848, titled “Treatment of Autism with Cannabidiol”

Company will sponsor sequencing and assembly at UC Davis to produce reference-grade genomes for several ecologically important organisms in the state of California